News & Media

202420232022202120202019201820172016201520142013
Press release 2017/09/14 Regulatory
Data monitoring committee gives “Go Ahead” in the MIV-711 osteoarthritis extension study

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) has again recommended continuation...

Read more
Press release 2017/09/11 Regulatory
Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Research & Development has decided to discontinue the development...

Read more
Press release 2017/08/18 Regulatory
Medivir initiates clinical study of birinapant in combination with KEYTRUDA® (pembrolizumab) in patients with treatment-refractory solid tumours

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the first patient has been enrolled in the company’s phase...

Read more
Press release 2017/08/18
Medivir licenses exclusive rights to MIV-802 for Greater China to Ascletis

Stockholm, Sweden and Hangzhou, China— Medivir AB (Nasdaq Stockholm: MVIR) and Ascletis today announce that Ascletis has licensed the exclusive rights...

Read more
Press release 2017/08/16
FDA accepts Medivir´s IND application for MIV-711, enabling clinical development in the US

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the Investigational New Drug (IND) application for MIV-711 has been...

Read more
Press release 2017/07/25 Regulatory
MEDIVIR AB – INTERIM REPORT, JANUARY – JUNE 2017

April - JuneSignificant events during the quarter Positive data from the phase II study of remetinostat in patients with early-stage cutaneous...

Read more
Press release 2017/06/19
Medivir appoints John Öhd as Chief Medical Officer

“I am pleased to appoint John Öhd, currently clinical R&D head, to the newly created position of Chief Medical Officer, reporting...

Read more
Press release 2017/06/09 Regulatory
Enrolment completed in the MIV-711 osteoarthritis extension study and data monitoring committee recommendation to “Go Ahead”

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces continued progress towards the completion of its phase IIa program for...

Read more
Press release 2017/05/30
Medivir’s CFO will leave his position - successor recruitment underway

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Ola Burmark, Chief Financial Officer at Medivir will be leaving...

Read more
Press release 2017/05/03 Regulatory
Resolutions at the Annual General Meeting in Medivir on 3 May 2017

Election of the board of directors and auditorThe annual general meeting in Medivir Aktiebolag (publ) on 3 May 2017 resolved, in...

Read more
Press release 2017/04/28 Regulatory
MEDIVIR AB – INTERIM REPORT, JANUARY – MARCH 2017

The quarter in brief Significant events during the first quarter The osteoarthritis trial evaluating MIV-711 received the go-ahead to continue without...

Read more
Press release 2017/04/24
Update on the development of simeprevir as part of the triple combination with AL-335 and odalasvir (JNJ-4178)

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today communicates an update on the status of the development of JNJ-4178, the...

Read more